Mali, the 20th African country to introduce malaria vaccination, will use a hybrid approach to boost protection during the high-risk part of the season.
In related news, the WHO marks World Malaria Day with a warning that progress against the mosquito-borne disease is stalling.
Both the CDC and NIH face cuts of more than 40%, according to an internal Trump administration document.
Malaria, HIV, and TB programs are already feeling impacts from the cuts, with scale-backs also depleting healthcare services in Afghanistan.
Seventeen African countries have introduced the vaccine, with 6 to 8 more expected to roll out programs in 2025.
Hyperuricemia was tied to serious complications such as kidney injury, a higher risk of death during or after hospitalization, and long-term cognitive impairment.
Dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine combined with amodiaquine reduced malaria incidence by 94% and 96%, respectively, compared with a control group.
Further tests found seasonal flu, rhinovirus, COVID, and other common respiratory viruses, alongside malaria and complications from malnutrition.
The WHO says it is monitoring some JN.1-related variants, still in low proportions, that might have more immune escape than XEC.
A man from the outbreak area recently died following hemorrhagic fever symptoms, and samples have been sent to Kinshasa for testing.
